Factor IX
Mechanism :
Coagulation Factor IX, is a purified protein produced by recombinant DNA technology for use in therapy of factor IX deficiency, known as hemophilia B or Christmas disease.
Indication :
- Factor IX deficiency
- Hemophilia B
Contraindications :
It should be used with caution, because of the potential risk of thromboembolic complications, in patients with liver disease, in post-operative patients, to neonates, or in patients at risk of thromboembolic phenomena or DIC. In each of these situations, the benefits of treatment with factor IX should be weighed against the risk of these complications.
Dosing :
1 unit/kg of
albumin fusion protein will increase factor IX levels by approximately 1% for children <12 years and 1.3% for children above 12 years. 1 unit/kg of recombinant factor will increase factor IX levels by approximately 0.7% for children <12 years. Give IV.
Estimated dose (units):
1 unit/body weight (kg) x desired factor IX increase (%)
Minor to moderate bleeds:
Uncomplicated hemarthroses, superficial muscle, or soft tissue:
Circulating Factor IX Activity Required: 30-60%
Dosing Interval: Every 48 hours
Duration of Therapy: 1 to 2 days.
Major bleeds:
Pharynx, retropharynx, retroperitoneum, CNS, major surgery prophylaxis:
Circulating Factor IX Activity Required: 80-100%
Dosing Interval: 6-12 hours, then once a day for 3 days and then very 48 hours till bleeding stops.
Bleeding prophylaxis:
Circulating Factor IX Activity Required: 50-80%
Dosing Interval: Every 24-48 hours
Duration of Therapy: 1 to 2 days.
Routine bleeding prophylaxis:
<12 years: 60 units/kg IV every week.
>12 years: 50 units/kg IV every week.
Adverse Effect :
Headache, flushing, fever, chills, vomiting, nausea, lethargy, or manifestations of allergic reactions.
Interaction :
Some products that may interact with this drug include: Drugs that help with clotting (e.g., tranexamic acid).
Hepatic Dose :
No dosage adjustments are recommended.